Nama Insights

Natera (NTRA)

Healthcare · Diagnostics Research · NASDAQ

Natera (NTRA) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $42.04B and a free-cash-flow yield of 0.2%. Over the most recent reported fiscal year, revenue grew 35.9% and free cash flow per share grew 18.2%. Nama's AI scorecard rates it Sell, 3.5 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 3.5/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Leading · +83.3% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-37.5%
How far the last close sits under the highest price of the past five years.
Market cap$42.04B
Trailing P/E—
Price / book22.4
Price / sales14.4
FCF yield0.2%
Dividend yield—
Gross margin65.1%
Operating margin-8.9%
Net margin-5.7%
Revenue growth (YoY)+35.9%
Revenue growth (3-yr annual)+41.1%
EPS growth (YoY)—
FCF/share growth (YoY)+18.2%
Beta1.5
ExchangeNASDAQ
SectorHealthcare
IndustryDiagnostics Research

NTRA earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.15). Beat the EPS estimate in 2 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 5, 2026 -$0.42 -$0.28 -50.0% $793.98M
Q2 2026 Aug 6, 2026 -$0.47 -$0.53 +11.3% $752.75M
Q1 2026 May 7, 2026 -$0.60 -$0.55 -9.1% $696.64M
Q4 2025 Feb 26, 2026 $0.36 -$0.53 +167.9% $665.50M

NTRA analyst price target

Median target $407.50 from 22 analysts, ranging $280.00 – $500.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $255.19B 27.9
DHR Danaher $160.10B 27.3
WAT Waters $89.71B 31.7
IDXX IDEXX Laboratories $54.33B 46.5
A Agilent Technologies $49.44B 28.9
IQV IQVIA $41.29B 19.6
MTD Mettler-Toledo International $33.93B 36.8
ILMN Illumina $30.34B 38.2
Explore live NTRA data on Nama Insights →

Recent Congressional trades

Natera trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Josh Gottheimer House Buy $1,001 - $15,000 Oct 15, 2025
Josh Gottheimer House Buy $1,001 - $15,000 Sep 5, 2025
Josh Gottheimer House Sell $1,001 - $15,000 Aug 11, 2025
Josh Gottheimer House Buy $1,001 - $15,000 Dec 5, 2024

NTRA FAQ

Is NTRA a buy?
Nama's AI scorecard currently rates Natera Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NTRA report earnings?
Natera's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.15.
What is the NTRA price target?
The median analyst price target from 22 analysts is $407.50, with a range of $280.00 – $500.00.
Is NTRA Shariah compliant?
Nama's AAOIFI-style screen reads Natera as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.